Acute Myeloid Leukemia

Dr Koehne Talks Hot Topics in Hematology at the Miami Cancer Institute Summit
Videos
Dr Koehne Talks Hot Topics in Hematology at the Miami Cancer Institute Summit
03/22/2021
Guenther Koehne, MD, discusses highlights from the Second Summit of the Americas on Immunotherapy for Hematologic Malignancies.
Guenther Koehne, MD, discusses highlights from the Second Summit of the Americas on Immunotherapy for Hematologic Malignancies.
Guenther Koehne, MD, discusses...
03/22/2021
Oncology
aw
Conference Insider
Exploring Dosing Regimens of Sabatolimab Therapy for MDS/AML
12/14/2020
Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS/AML.
Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS/AML.
Study findings support further...
12/14/2020
Oncology
News
Ruxolitinib Plus Azacitidine Tolerable for Advanced Phase MPN, Post-MPN AML
12/02/2020
Ruxolitinib combined with azacitidine was a well-tolerated therapy option for patients with advanced phase MPN and post-MPN AML.
Ruxolitinib combined with azacitidine was a well-tolerated therapy option for patients with advanced phase MPN and post-MPN AML.
Ruxolitinib combined with...
12/02/2020
Oncology
Mary-Beth Percival, MD, Talks Caring for AML Patients Amid a National Pandemic
Videos
Mary-Beth Percival, MD, Talks Caring for AML Patients Amid a National Pandemic
10/01/2020
Dr Percival discusses the provision of care to patients with AML during the COVID-19 pandemic.
Dr Percival discusses the provision of care to patients with AML during the COVID-19 pandemic.
Dr Percival discusses the...
10/01/2020
Oncology
Conference Insider
Challenges and New Horizons in the Treatment of Patients With AML
07/17/2020
During the Great Debates & Updates in Hematologic Malignancies, Gail Roboz, MD, discussed how clinicians can lead patients with AML down the correct treatment path.
During the Great Debates & Updates in Hematologic Malignancies, Gail Roboz, MD, discussed how clinicians can lead patients with AML down the correct treatment path.
During the Great Debates &...
07/17/2020
Oncology
Videos
Novel Therapies in AML
10/24/2019
Gail Roboz, MD, summarizes her presentation about novel therapies in AML at the 2019 Lymphoma & Myeloma Congress.
Gail Roboz, MD, summarizes her presentation about novel therapies in AML at the 2019 Lymphoma & Myeloma Congress.
Gail Roboz, MD, summarizes her...
10/24/2019
Oncology
Videos
Alternative Treatment Options for Older Patients With AML
10/23/2019
Sangmin Lee, MD, argued that venetoclax plus azacitidine, decitabine, and LDAC should not be the new standard care for older patients with AML.
Sangmin Lee, MD, argued that venetoclax plus azacitidine, decitabine, and LDAC should not be the new standard care for older patients with AML.
Sangmin Lee, MD, argued that...
10/23/2019
Oncology
Videos
Influx of New Therapies Exciting for Future of AML Treatment
03/23/2019
Daniel A. Pollyea, MD, MS, discusses all the recent drug approvals in AML and how they are changing clinical practice.
Daniel A. Pollyea, MD, MS, discusses all the recent drug approvals in AML and how they are changing clinical practice.
Daniel A. Pollyea, MD, MS,...
03/23/2019
Oncology
Podcasts
Early Results Show Promise With Venetoclax-Idasanutlin Combo for Relapsed/Refractory AML
12/20/2018
Gail Roboz, MD, discusses a recent trial involving the combination of venetoclax plus idasanutlin for patients with relapsed or refractory AML.
Gail Roboz, MD, discusses a recent trial involving the combination of venetoclax plus idasanutlin for patients with relapsed or refractory AML.
Gail Roboz, MD, discusses a...
12/20/2018
Oncology
Podcasts
Extended Decitabine Dosing Schedule Provides No Benefit Over Shorter Regimen in Newly Diagnosed AML
12/20/2018
Guillermo Garcia‑Manero, MD, discussed the clinical significance and potential implications of using a 5- versus 10-day decitabine dose schedule in patients with newly diagnosed AML.
Guillermo Garcia‑Manero, MD, discussed the clinical significance and potential implications of using a 5- versus 10-day decitabine dose schedule in patients with newly diagnosed AML.
Guillermo Garcia‑Manero, MD,...
12/20/2018
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use